Yoshio Hamada

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3641984/publications.pdf

Version: 2024-02-01

48 papers	1,282 citations	304602 22 h-index	377752 34 g-index
53 all docs	53 docs citations	53 times ranked	1083 citing authors

#	Article	IF	Citations
1	De novo design of a nanopore for single-molecule detection that incorporates a Î²-hairpin peptide. Nature Nanotechnology, 2022, 17, 67-75.	15.6	44
2	Mass Spectrometry-Based Solid Phase Peptide Reaction Assay for Detecting Allergenicity Using an Immobilized Peptide-Conjugating Photo-Cleavable Linker. International Journal of Molecular Sciences, 2020, 21, 8332.	1.8	1
3	Synthesis of Peptide-Immobilized Magnetic Beads, and Peptide Reactivity Assay for Assessing Skin Sensitization Utilizing Chromophore. Processes, 2020, 8, 1257.	1.3	2
4	Development of a chromophore-solid phase peptide reaction assay (C-SPRA) for assessing skin sensitization in vitro. Analyst, The, 2020, 145, 3211-3216.	1.7	2
5	Novel Purification Process for Amyloid Beta Peptide(1-40). Processes, 2020, 8, 464.	1.3	3
6	Peptidomimetic Synthesis: Drug Discovery for Alzheimerâ€™s Disease. Methods in Molecular Biology, 2020, 2103, 215-223.	0.4	0
7	Peptides for Silica Precipitation: Amino Acid Sequences for Directing Mineralization. Protein and Peptide Letters, 2018, 25, 15-24.	0.4	15
8	Editorial: Organic-Inorganic Hybrid Materials and Their Applications. Protein and Peptide Letters, 2018, 25, 2-3.	0.4	1
9	Recent progress in prodrug design strategies based on generally applicable modifications. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1627-1632.	1.0	31
10	Discovery of BACE1 Inhibitors for the Treatment of Alzheimerâ€™s Disease. , 2017, , .		1
11	DNA G-Wire Formation Using an Artificial Peptide is Controlled by Protease Activity. Molecules, 2017, 22, 1991.	1.7	15
12	Novel prodrugs with a spontaneous cleavable guanidine moiety. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1685-1689.	1.0	4
13	Site-specific control of multiple mineralizations using a designed peptide and DNA. Nanoscale, 2016, 8, 17081-17084.	2.8	6
14	New directions for protease inhibitors directed drug discovery. Biopolymers, 2016, 106, 563-579.	1.2	26
15	A novel N-terminal degradation reaction of peptides via N-amidination. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1690-1695.	1.0	4
16	Novel Î²-amyloid aggregation inhibitors possessing a turn mimic. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1572-1576.	1.0	18
17	Structureâ€“activity relationship study of BACE1 inhibitors possessing a chelidonic or 2,6-pyridinedicarboxylic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 618-623.	1.0	12
18	Aspartic protease inhibitors as drug candidates for treating various difficult-to-treat diseases. Amino Acids, Peptides and Proteins, 2014, , 114-147.	0.7	7

#	Article	IF	Citations
19	Novel BACE1 inhibitors with a non-acidic heterocycle at the P1â€² position. Bioorganic and Medicinal Chemistry, 2013, 21, 6665-6673.	1.4	12
20	Advances in the identification of Î²-secretase inhibitors. Expert Opinion on Drug Discovery, 2013, 8, 709-731.	2.5	29
21	BACE1 Inhibitor Peptides: Can an Infinitely Small k_{cat} Value Turn the Substrate of an Enzyme into Its Inhibitor?. ACS Medicinal Chemistry Letters, 2012, 3, 193-197.	1.3	23
22	The application of bioisosteres in drug design for novel drug discovery: focusing on acid protease inhibitors. Expert Opinion on Drug Discovery, 2012, 7, 903-922.	2.5	46
23	Novel BACE1 inhibitors possessing a 5-nitroisophthalic scaffold at the P2 position. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 4640-4644.	1.0	19
24	Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1130-1135.	1.0	24
25	Structure-guided design and synthesis of highly potent BACE1 inhibitors incorporating <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:mmultiscripts><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:none /><mml:mrow><mml:mo>â€²</mml:mo></mml:mrow></mml:mmultiscripts></mml:mrow></mml:math>	1.4	21
26	Design of pentapeptidic BACE1 inhibitors with carboxylic acid bioisosteres at <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"><mml:mrow><mml:msubsup><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mrow><mml:mn mathvariant="bold">1</mml:mn></mml:mrow><mml:mrow><mml:mo>â€²</mml:mo></mml:mrow></mml:msubsup></mml:mrow></m and P4 positions. Bioorganic and Medicinal Chemistry, 2010, 18, 3175-3186.	1.4	27
27	Tetrapeptides, as smallâ€sized peptidic inhibitors; synthesis and their inhibitory activity against BACE1. Journal of Peptide Science, 2010, 16, 257-262.	0.8	5
28	Significance of interactions of BACE1â€“Arg235 with its ligands and design of BACE1 inhibitors with P2 pyridine scaffold. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2435-2439.	1.0	36
29	Recent progress in the drug discovery of non-peptidic BACE1 inhibitors. Expert Opinion on Drug Discovery, 2009, 4, 391-416.	2.5	49
30	Racemization-free segment condensation based on the O-acyl isopeptide method: Toward a chemical protein synthesis on solid support. Advances in Experimental Medicine and Biology, 2009, 611, 161-162.	0.8	2
31	Design of Potent Aspartic Protease Inhibitors to Treat Various Diseases. Archiv Der Pharmazie, 2008, 341, 523-535.	2.1	60
32	Novel non-peptidic and small-sized BACE1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1654-1658.	1.0	46
33	BACE1 inhibitors: Optimization by replacing the <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si4.gif" overflow="scroll"><mml:mrow><mml:mmultiscripts><mml:mrow><mml:mtext>P</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:none /><mml:mrow><mml:mo>â€²</mml:mo></mml:mrow></mml:mmultiscripts></mml:mrow></mml:math> residue with non-acidic moiety. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1649-1653.	1.0	40
34	Combination of Non-natural <scp>d</scp>-Amino Acid Derivatives and Allophenylnorstatineâ^'Dimethylthioproline Scaffold in HIV Protease Inhibitors Have High Efficacy in Mutant HIV. Journal of Medicinal Chemistry, 2008, 51, 2992-3004.	2.9	42
35	Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating d-cysteine derivatives as P2/P3 moieties. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4213-4217.	1.0	25
36	Design and synthesis of potent Î²-secretase (BACE1) inhibitors with carboxylic acid bioisosteres. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2380-2386.	1.0	71

#	Article	IF	Citations
37	Î²-Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4354-4359.	1.0	55
38	Design and Synthesis of Î²-Secretase Inhibitors: Optimization at the P4 and P1â€² Positions. , 2006, , 599-600.		0
39	Design and synthesis of highly active Alzheimerâ€™s Î²-secretase (BACE1) inhibitors, KMI-420 and KMI-429, with enhanced chemical stability. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 211-215.	1.0	98
40	No Auxiliary, No Byproduct Strategy for Water-Soluble Prodrugs of Taxoids:Â Scope and Limitation of Oâ^'N Intramolecular Acyl and Acyloxy Migration Reactionsâ€. Journal of Medicinal Chemistry, 2005, 48, 2655-2666.	2.9	43
41	O?N intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides. Biopolymers, 2004, 76, 344-356.	1.2	74
42	Water-soluble prodrugs of dipeptide HIV protease inhibitors based on Oâ†'N intramolecular acyl migration: Design, synthesis and kinetic study. Bioorganic and Medicinal Chemistry, 2004, 12, 159-170.	1.4	42
43	Effect of the acyl groups on Oâ†'N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 2727-2730.	1.0	26
44	A Novel Approach of Water-Soluble Paclitaxel Prodrug with No Auxiliary and No Byproduct:â€‰ Design and Synthesis of Isotaxel. Journal of Medicinal Chemistry, 2003, 46, 3782-3784.	2.9	83
45	New water-soluble prodrugs of HIV protease inhibitors based on Oâ†'N intramolecular acyl migration. Bioorganic and Medicinal Chemistry, 2002, 10, 4155-4167.	1.4	53
46	Determination of Î±-amylase using a new blocked substrate. Clinica Chimica Acta, 1995, 234, 177-179.	0.5	6
47	Role of Pyridines in Medicinal Chemistry and Design of BACE1 Inhibitors Possessing a Pyridine Scaffold. , 0, , .		31
48	Isoacylpeptide Method for Long-Chain and Difficult Sequence-Containing Peptide Preparation. , 0, , .		0